Ginsenosides

vascular endothelial growth factor A ; Homo sapiens







11 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 35505354 Ginsenoside compound K inhibits the proliferation, migration and invasion of Eca109 cell via VEGF-A/Pi3k/Akt pathway. 2022 May 3 2
2 33192497 Corrigendum: Ginsenoside Re Attenuates High Glucose-Induced RF/6A Injury via Regulating PI3K/AKT Inhibited HIF-1a/VEGF Signaling Pathway. 2020 1
3 27655708 Clinical benefit from EGFR-TKI plus ginsenoside Rg3 in patients with advanced non-small cell lung cancer harboring EGFR active mutation. 2016 Oct 25 2
4 27800005 Ginsenoside Rg3 Serves as an Adjuvant Chemotherapeutic Agent and VEGF Inhibitor in the Treatment of Non-Small Cell Lung Cancer: A Meta-Analysis and Systematic Review. 2016 2
5 24375856 Ginsenoside Rg3 up-regulates the expression of vascular endothelial growth factor in human dermal papilla cells and mouse hair follicles. 2014 Jul 1
6 24691458 Ginsenoside Rg3 enhances radiosensitization of hypoxic oesophageal cancer cell lines through vascular endothelial growth factor and hypoxia inducible factor 1α. 2014 Jun 1
7 24966925 Ginsenoside Rg3 inhibits HIF-1α and VEGF expression in patient with acute leukemia via inhibiting the activation of PI3K/Akt and ERK1/2 pathways. 2014 1
8 22253055 Ginsenoside Rg3 inhibits endothelial progenitor cell differentiation through attenuation of VEGF-dependent Akt/eNOS signaling. 2012 Sep 2
9 19262553 Ginsenoside Rg1 promotes endothelial progenitor cell migration and proliferation. 2009 Mar 1
10 20218294 [The effects of ginsenosides Rg3 on the expressions of VEGF and KDR in human lung squamous cancer cells]. 2009 Nov 1
11 17253178 [Effect of adjuvant chemotherapy of ginsenoside Rg3 combined with mitomycin C and tegafur in advanced gastric cancer]. 2007 Jan 1